Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1

Comment

Jeffrey L Lennox et al. Ann Intern Med. 2015.

. 2015 Mar 17;162(6):461-2.

doi: 10.7326/L15-5066-3.

No abstract available

Comment on

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. Lennox JL, et al. Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Ann Intern Med. 2014. PMID: 25285539 Free PMC article. Clinical Trial.
Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
Stephan C. Stephan C. Ann Intern Med. 2015 Mar 17;162(6):460-1. doi: 10.7326/L15-5066. Ann Intern Med. 2015. PMID: 25775332 No abstract available.
Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
Lapadula G, Gori A. Lapadula G, et al. Ann Intern Med. 2015 Mar 17;162(6):461. doi: 10.7326/L15-5066-2. Ann Intern Med. 2015. PMID: 25775333 No abstract available.